Alnylam reports Q4 EPS (6c), consensus (14c)

Reports Q4 revenue $593.17M, consensus $580.62M. “2024 was another year of impressive execution for Alnylam (ALNY), generating product revenues of over $1.6 billion, reflecting growth of 33% compared to 2023, and highlighting the strength of our base business in hATTR-PN and Rare in both the U.S. and international markets. We look forward to potential global launches of vutrisiran in ATTR-CM this year, which will mark an inflection point for our TTR franchise and put us on a path to achieve the financial guidance we’ve provided,” said Yvonne Greenstreet, CEO of Alnylam. “Furthermore, driven by our proven RNAi platform, we anticipate 2025 will bring major advancements in our pipeline and expect to have over 25 high-value programs in the clinic across diverse indications by the end of the year. We’ve seen a remarkable pace of progress toward our Alnylam P5x25 goals and believe we are well positioned for the next half of the decade to continue delivering sustainable innovation to patients.”